HomeMarketsSharesFulgent Genetics, Inc.

Trade Fulgent Genetics, Inc. - FLGT CFD

Market is not available at the momentMarket information is presented
as of 2026-10-07T19:47:43+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.09
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.022262 %
(-$4.45)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.02226%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00004 %
($0.01)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


0.00004%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin5.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close20.53
Open20.09
1-Year Change-12.39%
Day's Range19.8 - 20.62

Trade Fulgent Genetics, Inc. - FLGT

Fulgent Genetics (FLGT) is a global molecular diagnostic and genetic testing services provider. 

Headquartered in Temple City, California, Fulgent Genetics was founded in 2011 as Fulgent Diagnostics. The company merges the fields of genetics, molecular biology and computer science to conduct diagnostic testing and genomic sequencing.It offers flexible testing options for physicians and patients. 

Fulgent Genetics’ portfolio consists of more than 18,000 single genes for genetic testing, 800 rare disease tests, complete genome sequencing, complete genome Copy Number Variation (CNVs) analysis, mitochondrial sequencing and CLIA/CAP quality sequencing services.

The company has received accreditations from the Clinical Laboratory Improvement Amendments (CLIA), the College of American Pathologists (CAP), the California Clinical Laboratory, the Pennsylvania Clinical Laboratory, the Maryland Medical Laboratory, the New York State Clinical Laboratory and the Rhode Island Laboratory. Its strategic partnership with Helio Health aims to help the company commercialise tests for blood-based early cancer detection. 

Fulgent Genetics Inc. stock began trading on the NASDAQ in 2016 under the ticker symbol FLGT. 

You can track the FLGT share value and price history live at http:/en-ke/en-kecapital.com.

Latest shares articles

A GameStop store in Portland, Oregon
GameStop stock forecast: debt exchange, Q2 profit
GameStop is a US video-game retailer. In Q2 fiscal 2026, net sales fell to $790.2m, while operating income rose to $160.2m. Explore third-party GME price targets and technical analysis. Past performance is not a reliable indicator of future results.
20 hours ago
Freenet stock forecast
Freenet stock forecast: revenue rises, EBITDA falls
Freenet reported first-half 2026 revenue of €1,512.9 million, up 24.7% year on year, while adjusted EBITDA fell 5.9% to €242.2 million and 2026 guidance was maintained. Explore third-party FNTN price targets and technicals. Past performance is not a reliable indicator of future results.
21 hours ago
Hims & Hers Health stock forecast
Hims & Hers Health stock forecast: FDA GLP-1 warning
Hims & Hers Health is a US telehealth company. In August 2026, the FDA issued a warning concerning unapproved compounded GLP-1 weight-loss drugs. Explore third-party HIMS price targets and technical analysis. Past performance is not a reliable indicator of future results.
22 hours ago
Arm Holdings stock forecast
Arm Holdings stock forecast: Haas flags AI demand
Arm Holdings is a UK-based semiconductor company. Chief executive Rene Haas said AI and data-centre demand showed no signs of slowing. Explore third-party ARM price targets and technical analysis. Past performance is not a reliable indicator of future results.
09:43, 6 October 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready